The presence of diabetes mellitus (DM) in patients with cardiovascular disease is associated with a greater number of major adverse events [1]. One of the most severe consequences is represented by heart failure (HF). A major role in the correct and swift diagnosis of HF in diabetic individuals could be attributed to specific biomarkers mentioned by the current clinical practice guidelines: NT-proBNP, Galectine-3 and sST2 [2]. Galectine-3 (Gal-3) was proved to have an important role in mediating myocardial fibrosis, inflammation and pathological cardiac remodeling, conferring it a high predictive value for future cardiovascular adverse events, like readmission for HF and overall mortality.
